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Monophosphorylation of cardiac troponin-I at Ser-23/24 is
sufficient to regulate cardiac myofibrillar Ca2 sensitivity
and calpain-induced proteolysis
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The acceleration of myocardial relaxation produced by -ad-
renoreceptor stimulation ismediated inpart byprotein kinaseA
(PKA)-mediated phosphorylation of cardiac troponin-I (cTnI),
which decreases myofibrillar Ca2 sensitivity. Previous evi-
dence suggests that phosphorylation of both Ser-23 and Ser-24
in cTnI is required for this Ca2 desensitization. PKA-mediated
phosphorylation also partially protects cTnI fromproteolysis by
calpain. Here we report that protein kinase D (PKD) phosphor-
ylates only one serine of cTnI Ser-23/24. To explore the func-
tional consequences of this monophosphorylation, we exam-
ined the Ca2 sensitivity of force production and susceptibility
of cTnI to calpain-mediated proteolysis when Ser-23/24 of cTnI
in mouse cardiac myofibrils was nonphosphorylated, mono-
phosphorylated, or bisphosphorylated (using sequential incuba-
tions in -phosphatase, PKD, and PKA, respectively). Phos-tag
gels, Western blotting, and high-resolution MS revealed that
PKD produced>90% monophosphorylation of cTnI, primarily
at Ser-24, whereas PKA led to cTnI bisphosphorylation exclu-
sively. PKD markedly decreased the Ca2 sensitivity of force
production in detergent-permeabilized ventricular trabeculae,
whereas subsequent incubationwithPKAproducedonly a small
further fall of Ca2 sensitivity. Unlike PKD, PKA also substan-
tially phosphorylated myosin-binding protein-C and signifi-
cantly accelerated cross-bridge kinetics (ktr). After phosphory-
lation by PKD or PKA, cTnI in isolated myofibrils was partially
protected from calpain-mediated degradation. We conclude
that cTnI monophosphorylation at Ser-23/24 decreases myo-
fibrillar Ca2 sensitivity and partially protects cTnI from cal-
pain-induced proteolysis. In healthy cardiomyocytes, the
basal monophosphorylation of cTnI may help tonically regu-
late myofibrillar Ca2 sensitivity.
Although cytosolicCa2 is the primary regulator ofmyofibril
contractile activity in cardiac cells, post-translationalmodifica-
tions of sarcomeric proteins play a major additional role in
modulating the Ca2 sensitivity and dynamic behavior of myo-
fibrils (1). For example, during stimulation of the cardiac
1-adrenoreceptor–Gs–adenylyl cyclase–cAMP signaling cas-
cade, protein kinase A (PKA)4 phosphorylates cardiac tro-
ponin-I (cTnI), thereby increasing the rate of Ca2 dissociation
from troponin-C (2) and decreasing myofibrillar Ca sensitivity.
Together with abbreviation of the intracellular Ca2 transient,
these cTnI-mediated effects contribute to the acceleration of
cardiac relaxation (lusitropic effect) during -adrenoreceptor
stimulation and may also contribute to the positive inotropic
effect (3, 4). Additionally, PKA-induced phosphorylation of
cardiac myosin–binding protein C (cMyBP-C) accelerates
myosin cross-bridge kinetics, which likely contributes to the
inotropic and lusitropic effects. It is well established that the
phosphorylation of cTnI by PKA occurs at both Ser-23 and
Ser-24 (Ser-22 and Ser-23 if the initiating methionine is not
counted) in theN terminus of cTnI, and previous evidence sug-
gests that phosphorylation of both serines is required for the
depression of Ca2 sensitivity (5, 6). With cMyBP-C, the PKA-
induced increase in cross-bridge kinetics is achieved by phos-
phorylation of serines 273, 282, and 302 in the M domain,
although single-site phosphorylation of Ser-282 by RSK (p90
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ribosomal S6 kinase) (7) or Ser-302 by protein kinase D (PKD)
(8) can have a similar effect.
PKA-mediated phosphorylation of cTnI and cMyBP-C also
regulates contractile function indirectly by reducing the sus-
ceptibility of these proteins to proteolysis. The Ca2-activated
protease calpain has been variously suggested to be responsible
for the cTnI C-terminal cleavage observed during ischemia/
reperfusion (I/R) (9), which may contribute to stunning (9, 10),
or for the N-terminal cleavage that has been seen in chronic
simulated microgravity (11), heart failure (12), and even in
healthy hearts (11). Phosphorylation of cTnI in vitro by PKA
has been found to slow the calpain-mediated degradation of
cTnI (13) (although at which cleavage site remains unclear) and
therefore could have a protective role in limiting cTnI contract-
ile dysfunction under these various conditions. Similarly, cleav-
age of cMyBP-C in the N terminus has been found during I/R,
leading to the formation of a poison peptide C0C2f fragment
that inhibits contractile function, and this cleavage is inhibited
by pseudophosphorylation of serines 273, 282, and 302 (14, 15).
In a previous study, we showed that PKD, an end effector of
the Gq–phospholipase C–diacylglycerolinositol 1,4,5-tris-
phosphate (InsP3) cascade, could mimic the functional effects
of PKA by decreasing myofibrillar Ca2 sensitivity via phos-
phorylation of cTnI Ser-23/24 and increasing cross-bridge
kinetics by phosphorylation of cMyBP-C at Ser-302 (8). We
assumed that the actions of PKDon cTnIwere, like PKA, due to
bisphosphorylation at Ser-23/24. However, we now find that
PKD phosphorylates only one of the Ser-23/24 sites. If this was
also true in our previous study (8), it would indicate thatmono-
phosphorylation at Ser-23/24 can regulate myofibrillar Ca2
sensitivity, contradicting the prevailing view (5, 6). To investi-
gate this possibility, we produced myofibril preparations in
which cTnI in the intact sarcomere is present with Ser-23/24
uniformly unphosphorylated, mono-phosphorylated (using
PKD), or bisphosphorylated (using PKA) and compared the
effects onmyofibrillar contractile performance and on the pro-
tection of cTnI from calpain-mediated proteolysis. An essential
part of this study was the development of a novel dephosphor-
ylation protocol to remove pre-existing phosphorylation from
the Ser-23/24 sites.Our data demonstrate thatmonophosphor-
ylation of cTnI at Ser-23/24 (predominantly Ser-24) regulates
the Ca2 sensitivity of cardiac myofibrils and partially protects
cTnI from calpain-induced proteolysis.
Results
Phosphorylation of cTnI by PKD or PKA in cardiacmyofibrils
We demonstrated previously that PKD phosphorylates cTnI
at Ser-23/24 (and cMyBP-C at Ser-302) in isolated myofibrils
(7, 8, 16). In our previous studies, cTnI phosphorylation was
assessed using a pSer-23/24 antibody, but in this study, we used
SDS-PAGE with Phos-tagTM reagent to quantify the different
phosphorylation states of cTnI (Phos-tag binds to phosphate
groups and retards protein migration according to the number
of phosphorylated residues on the protein). As Fig. 1 illustrates,
Phos-tag gels showed three different phosphorylation states of
cTnI, which we assigned on the basis that PKA is known to
produce bisphosphorylation of cTnI in the sarcomere. Even
before the addition of any kinase, there was basal phosphoryla-
tion of cTnI in these myofibrils, even though the mice had
received a -adrenoreceptor antagonist (Fig. 1A), with about
40% present as the monophosphorylated form (1P) and about
60% as the unphosphorylated form (0P). Unexpectedly, after
incubation of themyofibrils with constitutively active PKD, the
proportion of cTnI that was monophosphorylated increased to
more than 90%, but there was no statistically significant
increase in the proportion of the bisphosphorylated (2P) form.
Because the cTnI was basally phosphorylated before kinase
addition, the effects of PKD incubation on cTnI could not be
unambiguously interpreted. We therefore dephosphorylated
all subsequent myofibril preparations using  phosphatase
(-PP) prior to PKD incubation. This protocol (which included
additional steps to make it also suitable for use with skinned
trabeculae) removed all visible endogenous phosphorylation
from cTnI (Fig. 1B). Subsequent incubation with PKD induced
exclusively mono-phosphorylation of cTnI, which was com-
plete after 1 h of incubation.No statistically significant bisphos-
phorylation of TnI was observed even after 2 h of PKD
incubation.
As a check of the validity of these results, cTnI phosphoryla-
tion was assessed using a different technique: high-resolution
MS (Fig. 1C). In the-PP–treatedmyofibrils, the proportions of
un-, mono-, and bisphosphorylated forms of cTnI were 88%:
10%:2%, respectively. After incubation of themyofibrils in PKD,
the pattern changed to 5%:92%:3%, confirming that incubation
of the myofibrils in PKD almost exclusively resulted in mono-
phosphorylation of cTnI.
The above results provide no information about the cTnI
amino acid residue(s) targeted by PKD. To examine whether
the relevant cTnI site was one (or either) of the Ser-23/24 resi-
dues, -PP–treated myofibrils were incubated first with PKD
and then with PKA. As shown in Fig. 2A and Fig. S1, PKD
induced monophosphorylation of cTnI, whereas PKA induced
bisphosphorylation. There was no evidence for a trisphosphor-
ylated state of cTnI, indicating that the preferred target for PKD
was one of the “PKA” sites, i.e. Ser-23 or Ser-24. In support of
this, an antibody against pSer-23/24 cTnI recognized the PKD-
induced cTnI phosphorylation (Fig. 2A, bottom panel). Fur-
thermore,myofibrils from transgenic cTnI-Ala2mice (inwhich
Ser-23 and Ser-24 are mutated to nonphosphorylatable alanine
residues) remained unphosphorylated after PKD or PKA incu-
bations, confirming the identity of the phospho-acceptor resi-
due(s) that are selectively targeted by these kinases (Fig. 2B).
We conclude that PKD monophosphorylation occurs at the
Ser-23/24 sites in cTnI. It may be noted that the phosphoserine
23/24 cTnI antibody was not selective for the bisphosphorylat-
ed formof theproteinbutdetectedboth themono-andbisphos-
phorylated forms (Fig. 2, A and B), as reported previously (17).
To interrogate whether PKD targets Ser-23 or Ser-24, we
used a phosphorylation-specific antibody (mAb14) that has
been shown to selectively bind to pSer-24 in human cTnI (17).
This antibody did not recognize mouse phosphorylated cTnI,5
5 A. Martin-Garrido, B. J. Biesiadecki, H. E. Salhi, Y. Shaifta, C. G. dos Remedios,
S. Ayaz-Guner, W. Cai, Y. Ge, M. Avkiran, and J. C. Kentish, unpublished
results.
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so we repeated the PKD/PKA incubations using -PP–treated
myofibrils prepared fromhumandonor heart samples (Fig. 2C).
PKD induced monophosphorylation of cTnI in human myofi-
brils as in mouse myofibrils. There was substantial labeling of
both the mono- and bisphosphorylated forms of human cTnI
by the mAb14 antibody. Because there must be full phosphor-
ylation of Ser-24 in the bisphosphorylated samples, the appar-
ent similarity in the Ser-24 labeling intensities in the PKD-
treated and PKA-treatedmyofibrils would suggest thatmost, or
possibly all, of the monophosphorylation of PKD-treated cTnI
is at Ser-24.
Autoradiography using [32P]ATP was performed to investi-
gatewhetherothermyofibrillarproteinsweresignificantlyphos-
phorylated by PKD (and PKA). The autoradiogram (Fig. S2)
indicates that cTnI and, to a lesser extent, cMyBP-C were the
major myofilament proteins phosphorylated by either kinase.
To investigate the functional consequences of cTnI mono-
phosphorylation, we used the above dephosphorylation/phos-
phorylation protocol (Fig. 2) to produce sarcomeric cTnI in the
unphosphorylated,monophosphorylated,andbisphosphorylat-
ed forms and compared the effects on two factors known to be
influenced by cTnI phosphorylation: myofibrillar contractile
Figure 1. PKDmonophosphorylates cTnI in the sarcomere. A, mouse cardiac myofibrils were incubated in PKD for different times, separated in SDS-PAGE
with Phos-tag reagent, andblottedwith a specific antibody against cTnI. Top panel, representativeWestern blot. Bottompanel, relative abundance of the three
bands of cTnI in each lane. Symbols show the data from individual experiments; vertical bars show the mean  S.D. (n  3 experiments; *, p  0.05 versus
nontreated). IB, immunoblot. B, as A, except isolatedmyofibrils were incubatedwith -PP before incubation in PKD (n 4; *, p 0.05 versus nontreated). Note
that incubation with PKD produces monophosphorylation of cTnI almost exclusively. C, top-down high-resolutionMS analysis of cTnI frommousemyofibrils.
Top panel, representative total ion chromatogram showing separation and elution of cTnI. Bottom panel, high-resolution mass spectra of cTnI from -PP–
treatedmyofibrils before and after 1-h incubation of themyofibrils with PKD.Horizontal arrows indicate the position of unphosphorylated (cTnI), mono-phos-
phorylated (pcTnI), and bisphosphorylated cTnI (ppcTnI). Insets, isotopically resolved molecular ions with the calculated most abundant molecular weight
(Calc’d) based on the amino acid sequence and experimental most abundant molecular weight (Expt’l). Circles represent the theoretical isotopic abundance
distribution of the isotopomer peaks corresponding to the assigned mass.
Effects of cardiac TnI monophosphorylation at Ser-23/24
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performance and the protection of cTnI fromcalpain-mediated
proteolysis.
Effects of PKD or PKA onmyofibrillar Ca2 sensitivity and
cross-bridge kinetics
Myofibrillar Ca2 sensitivity and cross-bridge kinetics (ktr)
were measured in -PP–treated skinned trabeculae before and
after PKD incubation and then again after incubation in PKA
(Fig. 3 and Table S1). Time-matched controls were included
(no kinases) because pilot experiments showed that there was a
small but statistically significant decrease in Ca2 sensitivity
over the first hour or so of the experiment (Fig. 3B). The reason
for this is unclear, but it may be related to a time-dependent
reduction in titin-based passive force, which would decrease
myofibrillar Ca2 sensitivity (18). Incubation in PKD produced
a large decrease of Ca2 sensitivity, with the pCa50 (pCa for 50%
activation of force) falling from 6.00  0.04 to 5.68  0.03
(mean  S.E., n  10), a mean reduction of 0.32  0.01 (Fig.
3D). In contrast, the subsequent incubation in PKA (performed
in five experiments) produced only a small further decrease in
pCa50 from 5.70  0.01 to 5.59  0.01 (n  5), an additional
decrease of 0.11 0.01. If we subtract the mean pCa50 changes
in the corresponding time-matched controls, then the time-
independent fall in pCa50 is 0.24  0.03 for PKD (Fig. 3E) and
0.09 0.01 for PKA alone (after PKD). This suggests that most
of theCa2desensitizingactionofPKA-mediatedbisphosphor-
ylation of cTnI can bemimicked by PKD-mediatedmonophos-
phorylation alone. The maximum Ca2-activated force (Fmax)
generated by the trabeculaewas unaffected by the incubation in
PKD (Table S1). Fmax showed a small but significant decrease
with PKDPKA incubation compared with that in dephos-
phorylated muscles, but this was not statistically significant
compared with its corresponding time-matched control.
To check that the effect of PKD on Ca2 sensitivity was
mediated by phosphorylation at cTnI Ser-23/24, the experi-
ments were repeated with -PP–treated skinned trabeculae
from cTnI-Ala2 transgenic mice. Fig. 3C shows that Ca2 sen-
sitivity showed little or no change after incubation of these
muscles with PKD or PKDPKA. The pCa50 fell by 0.10 0.01
with PKD incubation, but this was not significantly different
from the small decrease seen in the time-matched control (Fig.
3D). We conclude that the Ca2-desensitizing action of PKD,
like PKA, requires the presence of phosphorylatable Ser-23 or
Ser-24 in cTnI.
In a previous study, we found that themonophosphorylation
of cMyBP-C at Ser-302 by PKD could accelerate ktr to the same
extent as produced by trisphosphorylation of cMyBP-C (at Ser-
273/282/302) by PKA (8). However, in that study, there was
basal phosphorylation of all three cMyBP-C serines. We there-
fore repeated these experiments using -PP–treated skinned
muscles. The rate of force redevelopment (ktr) varies with the
degree of Ca2 activation, i.e.with the relative force (19), so we
measured ktr over a range of forces and calculated the ktr at a
relative force of 50% of maximum (ktr50) by interpolation. The
results are shown in Fig. S3 and Table S1. Although incubation
in PKD alone tended to increase ktr50, this was not statistically
significant (Fig. S3D). In contrast, subsequent incubation with
PKA significantly increased relative ktr50 from 28.2%  3.6%
(post-PKD) to 37.5%  2.1%. Similar results were found with
experiments using cTnI-Ala2 mice (Fig. S3, C and D). There
was no change in ktr50 inWT time-matched controls. To inves-
tigate why PKD failed to accelerate cross-bridge kinetics signif-
icantly in this study, phospho-specific antibodies were used to
quantify the magnitude and pattern of cMyBP-C phosphoryla-
tion by PKD or PKA (Fig. S4). This confirmed our previous
finding (8) that PKD phosphorylates cMyBP-C preferentially at
Ser-302. However, in these -PP–treated myofibrils, the extent
of phosphorylation of Ser-302 by PKD amounted to only about
40% of the phosphorylation of this same site by PKA after PKD.
Figure2.DeterminationofthecTnIsitetargetedbyPKD.A, Phos-taggelsofmouse-PP–treatedmyofibrilsafter incubation inPKDalone(1h)orPKD(1h) followed
byPKA (1h).Westernblotsof Phos-taggelsused specific antibodies against total TnI orpSer-23/24TnI. IB, immunoblot.B, comparisonof results usingmyofibrils from
WTmiceor cTnI-Ala2 transgenicmice.Other conditionswereas forA.C,Westernblotsusinghuman-PP–treatedcardiacmyofibrils incubatedwithPKDaloneorPKD
followed by PKA and then probed for TnI or pSer-24 cTnI. Other conditionswere as forA. All gels are representative of at least three experiments.
Effects of cardiac TnI monophosphorylation at Ser-23/24
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Thus, with these myofibrils, the PKD incubation conditions
that produced full monophosphorylation of cTnI (Fig. 1) pro-
duced only partial phosphorylation of cMyBP-C Ser-302. Fig.
S4 also illustrates the effectiveness of the initial -PP treatment
in removing endogenous basal phosphorylation from these
three serines of cMyBP-C.
Protective effects of PKD and PKA on calpain-induced
proteolysis
Calpain has been implicated in the proteolysis of cTnI that
can occur in cardiac disease. Phosphorylation of the isolated
cardiac troponin complex by PKA slows the proteolysis of iso-
lated cTnI by calpain (13).We investigatedwhethermonophos-
phorylation by PKD or bisphosphorylation by PKA protects
cTnI in the intact sarcomere from calpain-dependent degrada-
tion. Myofibrils were treated with -PP and then PKD alone or
PKD followed by PKA. Calpain-1 was then added, and the pat-
tern of cTnI degradation was measured by immunoblotting
using a polyclonal antibody against the core sequences of tro-
ponin. Fig. 4, A–C, shows that incubation of the myofibrils in
calpain-1 led to rapid proteolysis of cTnI, with near-complete
loss of the full-length protein at the highest activity (30 units) of
calpain-1 used. Calpain incubation produced two main degra-
dation bands: the first band of a molecular mass of 22 kDa
appeared with both 10 units and 30 units of calpain and some-
times was seen as a doublet; the second band was of lower
molecular mass and became prominent only at the highest
activity of calpain. Prior treatment of cTnI with PKD partially
protected the full-length protein against subsequent calpain-
induced proteolysis, particularly that seen at 30 units of cal-
pain-1 (Fig. 4,A andC). Partial protection from proteolysis was
also observedwhen cTnI was first treatedwith PKDPKA (Fig.
4, B and C); in this case, about 50% of full-length cTnI was
preserved after 30-min incubation in 30 units of calpain. The
protective effects of PKD or PKDPKA incubation were not
significantly different (p 0.05).
Figure 3. Comparison of the effects of PKD and PKA on the force–Ca2 relationship of mouse skinned trabeculae. A, forces were measured in -PP–
treated skinned muscles before (Pre-kinase) and after incubations in PKD (PKD) and then PKA (PKDPKA). Forces expressed relative to that at 30 mol/liter
Ca2. Inset, mean pCa50 (log[Ca
2]) values. Symbols show the data from individual experiments; vertical bars show the mean  S.D. B, WT time-matched
controls (nokinase) corresponding toeach incubation inA.C, experiments as forAbutusing skinnedmuscles fromcTnI-Ala2mice.D, changes inCa2 sensitivity
(	pCa50) produced by PKD with or without PKA compared with WT time-matched controls. Data labeled PKD show the difference in pCa50 from the corre-
sponding prekinase pCa50. Data labeledPKA show the difference in pCa50 from the corresponding PKD pCa50.WT(t-m) are the time-matched controls (as in
B). E, the same data as inD but after subtraction of themean	pCa50 of the corresponding time-matched controls to illustrate the time-independent effects of
the kinases. For all panels, n 10 for the pre-kinase and PKD incubation groups in WT muscles, and n 5 for all other groups. ‡, p 0.0001; *, p 0.05; ns,
nonsignificant (all paired t tests, n 5 or n 10).
Effects of cardiac TnI monophosphorylation at Ser-23/24
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Previous reports have documented evidence for cTnI prote-
olysis within the C terminus or N terminus or both. To investi-
gate whether the degradation products in our study were the
results of N- or C-terminal cleavage of cTnI by calpain, we
repeated our experiments using an mAb specific for residues
190–196 in the C terminus of cTnI (Fig. 4, D–F). The results
confirmed that prior incubation in PKDor PKDPKApartially
protects cTnI from proteolysis (Fig. 4F). The C terminus anti-
body recognized the 22-kDa fragment(s) produced by calpain at
10 units or 30 units but not the lower-molecular-weight frag-
ment seen with the polyclonal antibody at 30 units of calpain.
This suggests that the first fragment retains the C terminus and
thus is likely to be a product of N terminus degradation,
whereas the second fragment lacks part or all of the C terminus
amino acids 190–196, so is likely to be the result of proteolysis
before or within this sequence. To explore the calpain proteol-
ysis sites further, we used the pSer-23/24 antibody that recog-
nizes pSer-23 and/or pSer-24 in the N terminus. This antibody
recognizes full-length cTnI when the protein has been phos-
phorylated by incubationwith PKDor PKDPKA (Fig. 1,C and
D). The results (Fig. S5) confirmed the gradual loss of the phos-
phorylated, full-length protein with calpain treatment, but the
antibody failed to detect any of the degradation products, sug-
gesting that both cTnI degradation products were missing the
N-terminal sequence up to at least serines 23/24. Finally, we
carried out the calpain experiments using myofibrils from
cTnI-Ala2mice (Fig. S6).With thesemyofibrils, the loss of full-
length cTnI and the appearance of one or two degradation
bands (depending on the antibody used) were unaffected by
prior incubation with PKDPKA; that is, the protective
effect of phosphorylation was absent. Together, these data
suggest that calpain leads to N-terminal and then C-terminal
proteolysis of cTnI in the myofibrils and that PKD-induced
monophosphorylation or PKA-induced bisphosphorylation
Figure4. Phosphorylationof sarcomeric cTnI byeitherPKDorPKA reduces its proteolysis by calpain.A,-PP–treated isolatedmyofibrilswere incubated
with PKD alone and then treated with calpain-1 at the activities shown (as units per 100l). Shown is representativeWestern blotting (WB) using an antibody
against full-length TnI and loading control (Coomassie stain). B, as A, except the myofibrils were incubated in PKD and then PKA before incubation in calpain.
C, summary of calpain-dependent cTnI degradation after no kinase addition (n  7), PKD alone (n  4), or PKDPKA (n  3). Symbols show the data from
individual experiments; vertical bars showthemeanS.D.D--F, asA–Cbutusinganantibody that recognizes a sequence in theC terminusof TnI. Symbols show
the data from individual experiments; vertical bars show the mean S.D. (n 6 for no kinase, n 4 for PKD alone, n 3 for PKDPKA). *, p 0.05 versus no
calpain; #, p 0.05 PKD or PKDPKA versus no kinase addition.
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of cTnI serines 23 and/or 24 can partially protect against this
proteolysis.
Calpain is also known to cleave cMyBP-C in the N-terminal
C0C2 domain, resulting in an N-terminal fragment (40 kDa).
Pseudophosphorylation of cMyBP-C at serines 273, 282, and
302 in intact hearts protects against cleavage (20). Fig. S7 shows
that 30 units of calpain produced near-complete loss of the
full-length cMyBP-C and appearance of the low-molecular-
weight fragment with a time course similar to the proteolysis of
cTnI. Prior treatment of dephosphorylated cardiac myofibrils
with PKD alone did not affect the proteolysis of cMyBP-C (Fig.
S7A), but this result is ambiguous because PKD incubation only
partially phosphorylated Ser-302 in cMyBP-C (Fig. S4). How-
ever, prior treatment with PKDPKA provided a near-com-
plete protective effect against calpain-induced cleavage (Fig.
S7B), showing that PKA-mediated phosphorylation of cMyBP-
C, like pseudophosphorylation, strongly protects this sarcom-
eric protein from calpain-mediated proteolysis.
Phosphorylation of cTnI and cMyBP-C by PKD or PKA in intact
myocytes
The experiments above were conducted using constitutively
active, recombinant PKD as a tool to induce monophosphory-
lation. Although PKD activity is low in healthy adult cardiac
tissue, the GqPCR/PKD pathway may become increasingly
important in heart failure (21). To investigate whether full-
length PKD can cause monophosphorylation in intact myo-
cytes, we examined the phosphorylation of cTnI in adult rat
ventricular myocytes (ARVMs) that had been transfected with
adenovirus encoding full-length PKD1 48 h previously. In these
myocytes, the PKC/PKD activators endothelin-1 and phorbol
12,13-dibutyrate produced modest and strong activation of
PKD, respectively, as measured by phosphorylation of PKD
Ser-744/748 (Fig. 5A). These agonists induced about 80%
monophosphorylation of cTnI without any significant bisphos-
phorylation (Fig. 5B). In contrast, PKAactivation by isoprotere-
nol led to cTnI bisphosphorylation exclusively. Activation of
PKD by PDBu or ET-1 also led to some phosphorylation of
cMyBP-C at Ser-302, although the increase in phosphorylation
level at this site was only 20–40% of that seenwith activation of
PKA (Fig. S8). These results showed that, in intact cardiomyo-
cytes, interventions that activate PKD induce monophosphor-
ylation of cTnI, as was the case with isolatedmyofibrils exposed
to exogenous PKD.
Discussion
Mammalian cardiac TnI hasmultiple potential phosphoryla-
tion sites that are targeted by a variety of kinases (1). Conse-
quently, cTnI integrates the activity of several signaling path-
ways to regulate myofibril contractile function. That PKA
phosphorylates cTnI at Ser-23 and Ser-24 is long-established,
and it is widely held that phosphorylation of both sites is needed
Figure 5. PKD canmonophosphorylate cTnI in rat adult cardiomyocytes. Cardiomyocytes infected with adenovirus carrying PKDWT/EGFP () or control
EGFP () were stimulated with ET-1 (100 nmol/liter for 5, 10, or 20 min), PDBu (200 nmol/liter, 20 min), or isoproterenol (Iso, 10 nmol/liter, 10 min). A,
representative immunoblots (IB) of p744/748 PKD and total PKD (top panel; the vertical line showswhere an empty lane has been removed) and relative levels
of p744/748 PKD normalized to total PKD (bottom panel). B, representative Phos-tag gels of total TnI and phosphoserine 23/24 cTnI (top panel) and proportion
of cTnI unphosphorylated, monophosphorylated, and bisphosphorylated cTnI after the various treatments. Symbols show the data from individual experi-
ments; vertical bars show the mean S.D. (n 3–5).
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to produce the decrease in myofibrillar Ca2 sensitivity. Here
we provide evidence that this is not the case and that phosphor-
ylation of just one site can regulate myofilament Ca2 sensitiv-
ity. This has implications for the regulation of contraction
under basal conditions and during inotropic stimulation. We
also show that both mono- and bisphosphorylation of cTnI at
Ser-23/24 can reduce its susceptibility to degradation by cal-
pain, thereby providing a potential protective role in cardiac
pathophysiology.
Basal myofilament phosphorylation
A common problemwith phosphorylation experiments with
isolated cardiac myofibrils or skinned myocytes/muscles is the
existence of a substantial and variable “basal” level of phosphor-
ylation of sarcomeric proteins, particularly cTnI and cMyBP-C.
With myofibrils from human tissue, the “healthy” heart sam-
ples usually derive from unused donor hearts from brain-dead
individuals kept on inotropic support; consequently, cTnI Ser-
23/24 phosphorylation in such samples can be high, e.g. about
1.3mol/mol of cTnI (65% ofmaximum) (17, 22). However, even
in diseased hearts, in which phosphorylation levels are lower,
there can be substantial Ser-23/24 monophosphorylation (17,
23). With myofibrils from animal tissue, basal phosphorylation
may be due to sympathetic stimulation during animal anesthe-
sia, but it is seen even in tissue from -blocker–treated animals
(Fig. 1A), so it could be due to a basal activity of intracellular
kinases. If functionally active, then this pre-existing phosphor-
ylation would blunt the effects of exogenous kinases added
experimentally. Prior attempts to fully dephosphorylate cTnI in
the sarcomere using exogenously added phosphatases have
been largely unsuccessful (24, 25). We report here that a pure,
recombinant phosphatase like -PP can be used to produce full
dephosphorylation of the Ser-23/24 sites on cTnI and of Ser-
273/282/302 on cMyBP-C in cardiac myofibrils (Fig. 1 and Fig-
ure S4), provided that the incubation solution lacks EGTA (see
supporting information). –PP requires Mn2 for its activity
(26), so the inhibitory effect of EGTAmay result from chelation
of this essential cofactor. The affinity of EGTA for Mn2 is
about 20 times greater than for Ca2 (27), so even when milli-
molar total MnCl2 is added to relaxing solution, the free con-
centration of Mn2 will be in the nanomolar range, well below
the 5 mol/liter Kd of -PP for Mn2 (26). Given that many
other phosphatases requiremetal ions ofMn2 or Zn2 (which
are also bound avidly by EGTA (27)) for catalytic activity, we
advise that EGTA should be avoided in dephosphorylation
solutions using these enzymes.
By putting the myofibrils into a “ground state” of zero phos-
phorylation in this way, we removed the confounding factor of
pre-existing phosphorylation of the myofibrils. Subsequent
incubation with PKD or PKA produced large decreases of myo-
fibrillar Ca2 sensitivity (total decrease by0.32 pCa units and
0.41, respectively; Fig. 3). These were much larger than in our
previous study (decreases of 0.1 and 0.15) (8). It is probable that,
in our previous study (and perhaps in similar studies by other
groups), the basal phosphorylation, which was likely to be pre-
dominantly monophosphorylation (Fig. 1A), had depressed
Ca2 sensitivity substantially before any kinases were added;
this would reduce the effects of kinases added subsequently.
This illustrates the need for prior dephosphorylation if the full
effects of phosphorylation on myofibrillar function are to be
established.
Monophosphorylation of cTnI decreases Ca2 sensitivity
We showed previously that PKD decreases the Ca2 sensi-
tivity of skinned cardiac muscles, and we assumed that PKD,
like PKA, acts via bisphosphorylation of Ser-23/24. This
assumption was based on Western blotting with a pSer-23/24
antibody and on the absence of PKD’s desensitizing effect in
muscles from cTnI-Ala2 mice. For a more detailed and quanti-
tative measurement of cTnI phosphorylation, in this work, we
used Phos-tag gel analysis, which showed that PKD phosphor-
ylates only one of the Ser-23/24 sites in mouse and human car-
diac myofibrils (Figs. 1 and 2). Mass spectrometry analysis of
cTnI confirmed this monophosphorylation. The ability of a
cTnI pSer-23/24 antibody to detect PKD-mediated phosphor-
ylation of cTnI in our previous study can be explained by the
finding that this antibody recognizes not only the bisphosphor-
ylated form of cTnI but also the monophosphorylated form
(Fig. 2), supporting a previous observation (17). ARVM exper-
iments (Fig. 5) showed that inotropic activation of full-length
PKD in intact cells also leads to phosphorylation of only one site
on cTnI.
Despite phosphorylating only one of the 23/24 serines, PKD
nevertheless produced a large fall in Ca2 sensitivity that was
only slightly less than with cTnI bisphosphorylation with PKA
(Fig. 3). Our finding that Ca2 sensitivity is regulated by mono-
phosphorylation disagrees with the orthodoxy that phosphor-
ylation of both Ser-23 and Ser-24 is required to decrease Ca2
sensitivity (i.e. that the 0P and 1P forms of cTnI are functionally
equivalent and confer the same, higher Ca2 sensitivity). This
concept originates from a study by Potter and co-workers (5),
who reconstituted a Tn complex containing cTnI Ser/Ala
mutants into pig skinned muscles; they found that the PKA-
induced fall of Ca2 sensitivity was not observed when either
Ser-23 or Ser-24 (or both)wasmutated to nonphosphorylatable
alanine. We cannot explain why our results differ from this,
although we note that, as judged by the recovery of force, tro-
ponin reconstitution was only 40–70% (5). More recently,
Wijnker et al. (6) used mutated human cTnI with phosphomi-
metic Ser3Asp substitutions to report that only the double
phosphomimetic substitution of Ser-23/24 led to reducedCa2
sensitivity in human skinned myocytes; single-site substitu-
tions had no effect. Although many studies have shown that
substitution of serine with aspartate is functionally equivalent
to serine phosphorylation, in fact, their side-chain structures
are considerably different. The carbonyl group of aspartate has
a net atomic weight of 44 and a charge of 1, whereas the
phosphate group of phosphoserine has a net atomic weight of
95 and a charge at neutral pH of approximately2 (28). Thus,
from both size and charge considerations, a double Ser3Asp
substitution at cTnI Ser-23/24 should be a bettermimic of cTnI
monophosphorylation than of bisphosphorylation. Whether
this explains the difference between the conclusions from our
study and that of Wijnker et al. (6) is not clear. Species-specific
differences cannot be ruled out. Another difference is that our
model allowed us to compare the endogenous cTnI within the
Effects of cardiac TnI monophosphorylation at Ser-23/24
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sarcomere when unphosphorylated, monophosphorylated, or
bisphosphorylated, without the need for exchange of mutated
cTnI.
Use of a pSer-24-specific antibody (17) helped to identify the
major target site for PKD in cTnI (Fig. 2C). The similarity in the
intensity of staining for the PKD-treated cTnI and the PKA-
treated cTnI (in which the Ser-24 site was fully phosphorylated
because there was only a 2P band), suggests that the phosphor-
ylation in the PKD-treated human cTnI was predominantly (or
entirely) at Ser-24. This agrees with our previous in vitro work
on PKD substrate preference using cTnI Ser3Ala mutants
reconstituted into a troponin complex with WT cTnT and
cTnC (16). It may be that PKD phosphorylates Ser-23 signifi-
cantly under other circumstances but not under the conditions
and time scale of our experiments, which allowed us to probe
the effects of monophosphorylation at the Ser-23/24 sites.
Most of the endogenous cTnI monophosphorylation in the
native myofibrils was also at the PKD-targeted site (Ser-24)
because PKD produced near-complete conversion of the 0P to
the 1P form but almost no conversion of the 1P to the 2P form
(Fig. 1A and Fig. S1). cTnI monophosphorylation has also been
observed in human hearts (17, 23). In the intact, healthy adult
cardiomyocyte, this basal phosphorylation is unlikely to be due
to PKD, which is present only at a low level, but probably due to
a residual activity of PKA or of other kinases known to phos-
phorylate cTnI at Ser-23/24 (29). Importantly, because this sin-
gle site regulates Ca2 sensitivity (as revealed by our PKD
experiments), basal monophosphorylation in intact myocytes
would provide a tonic regulation of basal Ca2 sensitivity; it
would also lessen the magnitude of any changes during subse-
quent inotropic activation, e.g. of PKA during 1-adrenorecep-
tor stimulation. We predict that the rate of Ca2 dissociation
from TnC, which determines Ca2 sensitivity and influences
myofilamentrelaxationrate,isalsocontrolledbycTnImonophos-
phorylation. Finally, the increased Ca2 sensitivity in skinned
preparations from failing or hypertrophic cardiomyopathy
hearts is presumed to be due to the decreased bisphosphoryla-
tion of cTnI (e.g. Ref. 30), but our study emphasizes the impor-
tance of changes in the monophosphorylated state of cTnI (17,
23). Fig. 5 shows that monophosphorylation can occur in cells
with sufficiently active PKD; this may occur during -adreno-
receptor stimulation in heart failure when the -adrenorecep-
tor pathway is down-regulated (21, 31).
A limitation of our study is that the functionalmeasurements
were made with skinned trabeculae, but their low protein con-
tent precludedmeasurements of phosphorylation,which there-
fore were carried out with skinned myocytes/myofibrils. How-
ever, if myofibrillar Ca2 sensitivity was controlled only by
cTnI bisphosphorylation (5, 6), then, to account for our results,
the samePKD incubation conditions that producedmonophos-
phorylation in isolatedmyofibrilsmust have produced bisphos-
phorylation in the skinned muscles. We cannot see how this
could occur. In fact, diffusional restrictions to enzyme move-
ment might be predicted to slow the rate of cTnI phosphoryla-
tion in skinned muscles compared with isolated myofibrils.
We reported (8) that PKD increases ktr by phosphorylating
Ser-302 on cMyBP-C. However, here the trend for cross-bridge
kinetics to increase was not statistically significant (Fig. S3).
This is probably because only 40% phosphorylation of Ser-
302 was observed, compared with 90% previously (8). The
reduced phosphorylation of cMyBP-C by PKD may be due to
loss of basal phosphorylation of Ser-282 during the -PP–
mediated dephosphorylation because phosphorylation of Ser-
282 appears to be necessary for the phosphorylation of Ser-302
in vitro (32). Thus, dephosphorylated cMyBP-C is a poorer
PKD substrate than is dephosphorylated cTnI.
If the Ca2 desensitizing action of cTnI bisphosphorylation
is largely reproduced by monophosphorylation, why are both
serines highly conserved (33)?One potential explanation is that
bisphosphorylation may control a myofilament property not
studied here, such as the sarcomere length dependence of Ca2
sensitivity (Frank-Starling effect) (34). Another possibility is
the monophosphorylated form of cTnI may be more suscepti-
ble than the bisphosphorylated form to the action of endoge-
nous phosphatases; that is, bisphosphorylation may have a
more prolonged effect.
Protection from calpain-induced proteolysis
In intact hearts, proteolysis of cTnI occurs during ischemia/
reperfusion, when C-terminal cleavage of cTnI forms a trun-
cated cTnI1–192 that may contribute to stunning by decreasing
the force-generating capacity of myofibrils (9, 10). Conversely,
N-terminal cleavage of 26 or 27 amino acids from cTnI was
observed in chronic simulated microgravity (11), heart failure
(12), and even in normal hearts (12) and mimicked Ser-23/24
phosphorylation by reducing myofibrillar Ca2 sensitivity and
accelerating muscle relaxation. Ca2-activated calpain may be
responsible for the C-terminal (9) or the N-terminal (12) cleav-
age. We found that calpain degrades sarcomeric cTnI, forming
two major TnI degradation products. The pattern and time
course of cTnI degradation (Fig. 4 and Figs. S4–S6) suggested
that the initial product resulted from cTnI N-terminal cleavage
at a site after Ser-23; this was then further degraded within the
C terminus to form the second product. This sequence is con-
trary to that found byMcDonough et al. (9), who reported that
I/R in rat hearts produced initial C-terminal cleavage to form
22-kDa cTnI1–193, with additional N-terminal cleavage to form
fragments cTnI63–193 and cTnI73–193 undermore severe condi-
tions. However, during I/R, other proteases may be activated,
and the low pH could alter the pattern of calpain-induced deg-
radation. The initial N-terminal degradation products we
observed are similar to those (21 kDa and 22 kDa) found in intact
hearts during simulated microgravity (11) and heart failure (12).
An initial N-terminal cleavage was also found with calpain-in-
duced proteolysis of recombinant cTnI (35). The twomainN-ter-
minal cleavage products in the intact hearts resulted from the loss
of amino acids 1–26 and 1–27, but we have no direct information
regarding the exact sites of cleavage in our study.
Calpain-induced proteolysis in the isolated troponin com-
plex is partly inhibited after phosphorylation of cTnI by PKA
(13). Here we confirm that bisphosphorylation of cTnI in intact
sarcomeres has a substantial, although incomplete, protective
effect (Fig. 4). A similar protective effect was also conferred by
monophosphorylation with PKD alone. If the first cleavage is at
N-terminal residues 26 or 27, then phosphorylation at serines
23 and/or 24 might interfere sterically with the nearby binding
Effects of cardiac TnI monophosphorylation at Ser-23/24
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of calpain. Alternatively, because phosphorylation at one or
both serines alters cTnI structure sufficiently to produce a large
fall of Ca2 sensitivity, the tertiary structure and flexibility of
the regulatory N-terminal sequence will be changed, and this
could inhibit binding of calpain.
Like cTnI, cMyBP-C is degraded during myocardial ische-
mia, although in this case, proteolysis occurs in theN terminus,
forming a 40-kDa C0C1f fragment that may act as a poison
peptide (20). cMyBP-C is a substrate for calpain, and pseudo-
phosphorylation of the three serines within this sequence (273,
282, and 302) makes the protein less susceptible to proteolysis
(14, 15). We found that the native cMyBP-C protein within the
sarcomere is degraded by calpain with a time course similar to
that for proteolysis of cTnI (Fig. S7). Trisphosphorylation of
cMyBP-C with PKA, like pseudophosphorylation, provided
complete protection against this proteolysis, at least under the
conditions of our experiment. We were unable to establish
whether monophosphorylation of cMyBP-C (at Ser-302) by
PKD also has a protective effect because PKD produced only a
low level of cMyBP-C Ser-302 phosphorylation under the incu-
bation conditions used.
In summary, our results demonstrate that monophosphory-
lation of cTnI, primarily at Ser-24, affects both myofibrillar
Ca2 sensitivity and the susceptibility of cTnI to calpain-in-
duced proteolysis. These effects are more similar functionally
to those conferred by cTnI in its bisphosphorylated form, not in
its unphosphorylated form.
Experimental procedures
An expanded Methods section is provided in the supporting
information.
Ethics statement
Experiments usingmouse trabeculae and rat cardiomyocytes
were performed in accordance with the Guidance on the Oper-
ation of Animals (Scientific Procedures) Act, 1986 (UK) and
the Directive of the European Parliament (2010/63/EU) and
received approval from the King’s College London Ethics
Review Board. Human samples were obtained after informed
consent andwith approval of theHumanResearch Ethics Com-
mittee of the University of Sydney (approval 2012/2814). This
investigation conformed with the principles in the Declaration
of Helsinki (1997).
Assessment ofmyofibril contractile function in skinned
trabeculae
The methods for preparing mouse skinned trabeculae and
for measuring their Ca2 sensitivity and cross-bridge cycling
kinetics have been described previously (8). In brief, thin trabe-
culae were prepared from the right ventricles of WT mice or
cTnI-Ala2 transgenic mice (mice that express cTnI in which
Ser-23 and Ser-24 are replaced by two nonphosphorylatable
Ala residues on a cTnI-null background (8)) and were permea-
bilized with Triton X-100. The skinned trabeculae were bathed
in relaxing solution (free [Ca2], 1 nmol/liter; pCa, 9) and
clamped to a force transducer andhigh-speed length controller.
Force and cross-bridge cycling kinetics were measured at 18 °C
in a series of calcium/EGTA activating solutions containing
0.2–30 mol/liter free Ca2 (pCa 6.7–4.5). Cross-bridge cycle
kinetics were assessed by performing a rapid release–restretch
maneuver to forcibly detach the cross-bridges; the ktr when
cross-bridges reattach and generate force after the restretch
was used as an index of cross-bridge kinetics (8, 36, 37).
Initial dephosphorylation ofmyofibrils
Although the mice were treated with a -adrenoreceptor
antagonist before euthanasia (see supporting information), the
detergent-treated muscles or isolated myofibrils nevertheless
exhibited substantial endogenous phosphorylation of cTnI
(Fig. 1A). To remove this endogenous phosphorylation, we first
incubated the skinned trabeculae in -PP. However, in pilot
experiments we found that -PP was inhibited in relaxing solu-
tion, probably because of binding of itsMn2 cofactor by EGTA
(see “Discussion”). On the other hand, EGTA is normally
required in relaxing solution to avoid a large and potentially
damaging Ca2-activated contracture caused by contaminant
Ca2. We therefore devised a novel dephosphorylation proce-
dure in which the trabeculae were first put into a low-force
rigor contracture by removing ATP in the presence of EGTA,
and then EGTA was removed and -PP applied. Upon return to
relaxing solution, themuscle and its sarcomeres showedno visible
damage. This sequence of solutions, but performed instead with
skinned myocyte fragments and myofibrils (see supporting infor-
mation), led toalmost completedephosphorylationof cTnI (Fig. 1,
B and C) and cMyBP-C (Fig. S4). The same protocol was used to
prepare dephosphorylated myofibrils from left ventricular sam-
ples from human (unused donor) hearts.
Contractile effects of PKD- and PKA-induced phosphorylation
The overall experimental protocol consisted of first measur-
ing the Ca2 sensitivity of force and ktr in the trabeculae using
the standard relaxing and activating solutions after incubation
in -PP, then again after incubation in constitutively active
PKD, and finally (for a subset of muscles) after incubation in
PKA catalytic subunit. The phosphatase inhibitor calyculin A
was included in all solutions following -PP incubation. With
this protocol, each trabecula served as its own control, allowing
paired comparison of pre- and post-kinase data. Time-matched
controls were included, in which -PP-treated muscles were
subjected to the identical incubation protocols except that PKD
and PKA were omitted.
Assessment ofmyofibril protein phosphorylation
The trabeculae contained insufficient tissue to allow mea-
surement of their myofibril phosphorylation, so instead we
prepared suspensions of skinned myocyte fragments and myo-
fibrils (herein collectively referred to as myofibrils) by homog-
enization of ventricular tissue. Myofibrils were treated with the
same dephosphorylation/phosphorylation protocols and solu-
tions as used for the trabeculae. The extent and pattern of phos-
phorylation of cTnI and cMyBP-C in the myofibrils was mea-
sured by immunoblot analysis after either standard SDS-PAGE
or Phos-tagTM phosphate affinity SDS-PAGE. For one set of
PKD-treated myofibrils, we assessed the phosphorylation of
cTnI using high-resolution MS (38).
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PKD- or PKA-induced phosphorylation in cultured ARVMs
overexpressing PKD
AVRMs were isolated and infected with a PKD1WT-EGFP
adenovirus or EGFP adenovirus control (39). After 48 h in cul-
ture, ARVMs were bathed in a HEPES–Krebs solution and
stimulated with isoproterenol (10 nmol/liter), endothelin-1
(ET-1, 100 nmol/liter), or phorbol 12,13-dibutyrate (PDBu, 200
nmol/liter). Myofibril phosphorylation was then determined.
Source of chemicals
Primary antibodies—Cell Signaling Technology supplied the
phosphospecific antibody against pSer-23/24 cTnI (4004) and
the rabbit anti-TnI polyclonal antibody (4002) that was used to
label total TnI. The phosphospecific antibody against pSer-24
of human cTnI was a kind gift from Steven Marston. A mouse
anti-cTnI mAb, with an epitope of residues 190–196 of cTnI,
was from Hytest (MF4). Phosphospecific antibodies against
pSer-273, pSer-282, and pSer-302 of cMyBP-C (40) were kind
gifts from Sakthivel Sadayappan and Jeffrey Robbins. Primary
antibodies against PKD phosphoserine 744/748 (2054) and
total PKD (C20) were obtained fromCell Signaling Technology
and Santa Cruz Biotechnology, respectively.
Adenovirus—A recombinant adenovirus (AdV:PKDWT/
EGFP) encoding full-length WT mouse PKD1 (PKDWT) and
enhanced GFP (EGFP) downstream of separate cytomegalovi-
rus promoters was as described previously (39).
Enzymes—PKAcatalytic subunit (539576, frombovine heart)
was from Calbiochem/Merck-Millipore, and  phosphatase
was fromNewEngland Biolabs (P0753S, 20,000 units/g). PKD
was a recombinant PKD1 catalytic domain expressed in Sf21
insect cells; this is constitutively active in the absence of the
autoinhibitory N-terminal domain (16). Calpain (1000 units/
mg, from human erythrocytes) and endothelin-1 were from
Calbiochem.Other reagents are detailed in the supporting data.
Statistics
Graphical statistics are shown as individual symbols and
mean  S.D.; some numerical data are listed as mean  S.E.
Statistical comparisons were by paired or unpaired Student’s t
test, as appropriate, when comparing data between two groups
or by analysis of variance followed by the Bonferroni test when
comparing data betweenmultiple groups. p 0.05 was consid-
ered statistically significant.
Author contributions—A. M.-G., M. A., and J. C. K. conceptualiza-
tion; A. M.-G., Y. S., C. G. d. R., S. A.-G., W. C., Y. G., M. A., and
J. C. K. data curation; A. M.-G., Y. S., C. G. d. R., S. A.-G., and J. C. K.
formal analysis; A. M.-G., Y. S., C. G. d. R., S. A.-G., W. C., Y. G.,
M. A., and J. C. K. validation; A. M.-G., B. J. B., H. E. S., Y. S., C. G. d.
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